Ensuring appropriate tumor testing can help you identify options for targeted therapies. Test your patients for genomic alterations and use approved biomarker tests to identify patients eligible for newer precision medicine treatments. Treating eligible patients with targeted therapies has shown to be effective.

NSCLC Pathology and Molecular Testing – What Should Clinicians Know? – On Demand Webinar

CAP/IASLC/AMP Molecular Testing Guideline

IASLC Atlas of EGFR Testing in Lung Cancer

IASLC Atlas of PD-L1 Testing in Lung Cancer

IASLC Atlas of ALK and ROS1 Testing in Lung Cancer

Molecular Testing in the Community Setting – Resources & Tools for the Multidisciplinary Team – ACCC Website

Testing and Treating ALK+ Non-Small Cell Lung Cancer – ACCC Website

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens in Journal of Thoracic Oncology – Open Access Article

For some patients, traditional chemotherapy, available targeted therapies, or radiation may not be the best option. However, clinical trials may be a good alternative. Clinical trials are an option for any patient with cancer per the National Comprehensive Cancer Network’s guidelines. Exciting new research studies may provide improved outcomes for patients with lung cancer. Considering options for clinical trials in initial treatment discussions can help ensure that patients are not excluded from any trials based on previous treatments. Enrollment in clinical trials tends to be low and patients who are not offered an appropriate trial may be missing the opportunity to receive cutting-edge treatment and excellent care.

Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity in Journal of Thoracic Oncology – Open Access Article

Optimal Care Coordination Model for Lung Cancer Patients on Medicaid – ACCC Website

LungMATCH – LCA Website